I cannot see the wood for the tress in this 20 page chat. There is so much noise, it's really hard to see the big picture, have had to have it summarised for me again. Hope this is useful for some people.
There is actually quite a lot of common ground.
Almost everyone agrees that:
• The existing evidence for puberty blockers is very poor.
• The Tavistock failed to collect adequate long-term outcome data.
• Children experiencing serious distress need proper psychological and safeguarding support.
• Private, overseas and illegal access to blockers is a genuine problem.
• Better evidence and long-term follow-up are needed.
The disagreement is about whether this particular trial is an ethical or useful way to obtain that evidence.
Looking at distinct posters rather than simply counting posts, I would estimate that roughly 85 to 90% oppose the trial as currently proposed. Around 5 to 10% support it, with a small number being uncertain or conditionally supportive.
The apparent balance of the discussion is misleading because a large proportion of the pro-trial posts come from only two or three very persistent contributors.
The main objections supported by the large majority are:
1. The study does not clearly define what success would mean
Surely the meaningful clinical success would be the cessation or substantial reduction of gender dysphoria, allowing the child to become comfortable with their developing body and no longer require medical transition.
Instead, the proposed outcomes appear largely concerned with short-term measures of distress, wellbeing or satisfaction. A child may feel temporarily relieved because they have received the treatment they wanted, while their underlying dysphoria remains unchanged or becomes more firmly embedded.
A short-term improvement in mood is not evidence that the treatment has resolved the condition it is supposedly treating.
2. It cannot answer the important long-term questions
A study lasting one or two years cannot properly determine effects on:
• fertility and future sexual function
• bone density and fracture risk
• cognitive and neurological development
• adult physical and mental health
• regret or later detransition
• the effects of subsequent hormones and surgery
Many of the most important outcomes may not become apparent until well into adulthood.
3. The effect of blockers cannot be separated from the rest of the pathway
If most participants later proceed to cross-sex hormones, it will become extremely difficult to separate the consequences of puberty blockers from the consequences of hormones, surgery and continued social transition.
Blockers cannot realistically be assessed as an isolated intervention when they commonly function as the first medical step in a longer pathway.
4. The outcomes are subjective and vulnerable to bias
The children and families will know whether they have received blockers. Many will already strongly want the treatment and may regard receiving it as validation.
That creates obvious placebo, expectation and reporting effects. The study may detect short-term satisfaction with receiving treatment rather than any objective therapeutic benefit.
5. There is no adequate non-medical comparison
Many posters believe the proper comparison should be comprehensive psychological, family and safeguarding support without reinforcing a cross-sex identity or placing the child on a medical pathway.
Without that, the study may compare blockers against an artificially weak alternative rather than against the best possible non-medical care.
6. Meaningful consent is doubtful
Children cannot fully understand uncertain risks to fertility, sexual function, adult relationships, bone health or lifelong medical dependency.
Parents are also being asked to consent without reliable long-term evidence. That is the very evidence the study says it is trying to create.
7. Existing patients should be followed up first
The dominant view is not “do no research”. It is that the NHS should first complete the promised data-linkage work on the thousands of young people who have already received blockers.
Their later records could provide information about hormones, surgery, mental health, physical health and long-term outcomes without deliberately exposing another cohort.
The vocal minority’s strongest argument is that historical records are incomplete and confounded, and that only a prospective controlled study will produce evidence capable of persuading international clinicians. They also argue that some children will obtain drugs privately or illegally anyway, so supervised access may reduce harm.
That is a coherent argument, but most posters remain unconvinced because they do not believe this protocol will produce the decisive long-term evidence being promised.
The broad majority position is therefore:
Research is needed, but this trial is too short, too subjective, too poorly defined and too entangled with the wider medical-transition pathway to establish whether blockers actually resolve gender dysphoria or improve children’s long-term lives.